Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald L Denardo

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancerRobert Ivkov, Sally J DeNardo, Wolfgang Daum, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 30, 2007
Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cellsJeremy West, Julie Perkins, Saphon Hok, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 2, 2003
Application of MINERVA Monte Carlo simulations to targeted radionuclide therapyMarie-Anne Descalle, Christine L Hartmann Siantar, Lucile Dauffy, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 7, 2007
Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphomaOrazio Schillaci, Gerald L DeNardo, Sally J DeNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapySally J DeNardo, Gerald L DeNardo, Laird A Miers, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 3, 2007
Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in miceSally J DeNardo, Gerald L DeNardo, Arutselvan Natarajan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugatesGerald L DeNardo, Sally J DeNardo, James J Peterson, et al.
The Prostate|January 5, 2002
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6Robert T O'Donnell, Sally J DeNardo, Laird A Miers, et al.
Cancer|March 6, 2002
Rationales, evidence, and design considerations for fractionated radioimmunotherapyGerald L DeNardo, Jeffery Schlom, Donald J Buchsbaum, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 7, 2010
Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imagingGerald L DeNardo, Arutselvan Natarajan, Saphon Hok, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancerRobert Ivkov, Sally J DeNardo, Wolfgang Daum, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 30, 2007
Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cellsJeremy West, Julie Perkins, Saphon Hok, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 2, 2003
Application of MINERVA Monte Carlo simulations to targeted radionuclide therapyMarie-Anne Descalle, Christine L Hartmann Siantar, Lucile Dauffy, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 7, 2007
Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphomaOrazio Schillaci, Gerald L DeNardo, Sally J DeNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapySally J DeNardo, Gerald L DeNardo, Laird A Miers, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 3, 2007
Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in miceSally J DeNardo, Gerald L DeNardo, Arutselvan Natarajan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugatesGerald L DeNardo, Sally J DeNardo, James J Peterson, et al.
The Prostate|January 5, 2002
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6Robert T O'Donnell, Sally J DeNardo, Laird A Miers, et al.
Cancer|March 6, 2002
Rationales, evidence, and design considerations for fractionated radioimmunotherapyGerald L DeNardo, Jeffery Schlom, Donald J Buchsbaum, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 7, 2010
Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imagingGerald L DeNardo, Arutselvan Natarajan, Saphon Hok, et al.
Pageof 7